CYTR Stock Overview
CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.13|
|52 Week High||US$4.70|
|52 Week Low||US$0.094|
|1 Month Change||1.56%|
|3 Month Change||-71.89%|
|1 Year Change||-90.30%|
|3 Year Change||-76.99%|
|5 Year Change||-95.70%|
|Change since IPO||-99.98%|
Recent News & Updates
|CYTR||US Biotechs||US Market|
Return vs Industry: CYTR underperformed the US Biotechs industry which returned -19.5% over the past year.
Return vs Market: CYTR underperformed the US Market which returned -8.1% over the past year.
|CYTR Average Weekly Movement||19.2%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: CYTR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: CYTR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company’s lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor.
CytRx Fundamentals Summary
|CYTR fundamental statistics|
Is CYTR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYTR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||0.00%|
How did CYTR perform over the long term?See historical performance and comparison
Is CytRx undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CYTR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CYTR's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: CYTR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CYTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYTR is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (1.5x).
How is CytRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has CytRx performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYTR is currently unprofitable.
Growing Profit Margin: CYTR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYTR is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.
Accelerating Growth: Unable to compare CYTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CYTR has a negative Return on Equity (-402.5%), as it is currently unprofitable.
How is CytRx's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CYTR's short term assets ($6.2M) exceed its short term liabilities ($3.1M).
Long Term Liabilities: CYTR's short term assets ($6.2M) exceed its long term liabilities ($186.1K).
Debt to Equity History and Analysis
Debt Level: CYTR is debt free.
Reducing Debt: CYTR has no debt compared to 5 years ago when its debt to equity ratio was 163.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYTR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CYTR has less than a year of cash runway if free cash flow continues to grow at historical rates of 40.5% each year.
What is CytRx current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYTR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CYTR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Snowdy (51 yo)
Dr. Stephen Snowdy, Ph D., serves as Chief Executive Officer at CytRx Corporation since January 10, 2022. He served as Chief Executive Officer of Visioneering Technologies, Inc. since June 2013 until Janua...
Experienced Management: CYTR's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: CYTR's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
CytRx Corporation's employee growth, exchange listings and data sources
- Name: CytRx Corporation
- Ticker: CYTR
- Exchange: OTCPK
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.475m
- Shares outstanding: 43.48m
- Website: https://www.cytrx.com
Number of Employees
- CytRx Corporation
- 11726 San Vicente Boulevard
- Suite 650
- Los Angeles
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.